Citadel Advisors
ITCI

Citadel Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Citadel Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,237,131
Closed -$295M – 15783
2025
Q1 		$295M Buy
2,237,131
+2,119,110
+1,796% +$264M 0.06% 257
2024
Q4 		$9.86M Buy
+118,021
New +$9.7M ﹤0.01% 3006
2024
Q3 		– Sell
-133,673
Closed -$10M – 15492
2024
Q2 		$9.16M Sell
133,673
-227,621
-63% -$15.8M ﹤0.01% 2874
2024
Q1 		$25M Buy
361,294
+325,722
+916% +$22.4M ﹤0.01% 1849
2023
Q4 		$2.55M Sell
35,572
-49,610
-58% -$2.85M ﹤0.01% 4947
2023
Q3 		$4.44M Buy
85,182
+61,089
+254% +$3.56M ﹤0.01% 3857
2023
Q2 		$1.53M Sell
24,093
-589,663
-96% -$36.7M ﹤0.01% 5651
2023
Q1 		$33.2M Sell
613,756
-48,107
-7% -$2.33M 0.01% 1444
2022
Q4 		$35M Buy
661,863
+477,231
+258% +$23.9M 0.01% 1416
2022
Q3 		$8.59M Sell
184,632
-221,099
-54% -$11.5M ﹤0.01% 2993
2022
Q2 		$23.2M Sell
405,731
-193,301
-32% -$11M 0.01% 1692
2022
Q1 		$36.7M Sell
599,032
-151,684
-20% -$7.88M 0.01% 1364
2021
Q4 		$39.3M Sell
750,716
-425,749
-36% -$17.9M 0.01% 1369
2021
Q3 		$43.9M Sell
1,176,465
-384,927
-25% -$13.4M 0.01% 1241
2021
Q2 		$63.7M Buy
1,561,392
+65,386
+4% +$2.42M 0.01% 942
2021
Q1 		$50.8M Buy
1,496,006
+70,320
+5% +$2.44M 0.01% 1031
2020
Q4 		$45.3M Buy
1,425,686
+342,124
+32% +$8.99M 0.01% 1022
2020
Q3 		$27.8M Buy
1,083,562
+582,002
+116% +$13.3M 0.01% 1292
2020
Q2 		$12.9M Buy
501,560
+242,173
+93% +$4.9M ﹤0.01% 1957
2020
Q1 		$3.99M Sell
259,387
-361,527
-58% -$7.85M ﹤0.01% 3035
2019
Q4 		$21.3M Sell
620,914
-85,407
-12% -$1.03M 0.01% 1420
2019
Q3 		$5.28M Buy
706,321
+366,673
+108% +$3.52M ﹤0.01% 3041
2019
Q2 		$4.41M Buy
339,648
+246,976
+267% +$3.17M ﹤0.01% 3285
2019
Q1 		$1.13M Sell
92,672
-955,461
-91% -$12.2M ﹤0.01% 5378
2018
Q4 		$11.9M Buy
1,048,133
+269,940
+35% +$4.36M 0.01% 1705
2018
Q3 		$16.9M Sell
778,193
-543,531
-41% -$11.4M 0.01% 1553
2018
Q2 		$23.4M Buy
1,321,724
+167,197
+14% +$3.39M 0.01% 1180
2018
Q1 		$24.3M Buy
1,154,527
+972,589
+535% +$18.9M 0.01% 979
2017
Q4 		$2.63M Buy
181,938
+114,606
+170% +$1.77M ﹤0.01% 3260
2017
Q3 		$1.06M Sell
67,332
-1,331,461
-95% -$19.5M ﹤0.01% 4234
2017
Q2 		$17.4M Buy
1,398,793
+598,266
+75% +$6.94M 0.01% 1079
2017
Q1 		$13M Sell
800,527
-462,955
-37% -$6.7M 0.01% 1242
2016
Q4 		$19.1M Buy
1,263,482
+1,206,185
+2,105% +$17M 0.02% 913
2016
Q3 		$873K Buy
57,297
+34,426
+151% +$1.39M ﹤0.01% 4022
2016
Q2 		$888K Buy
22,871
+13,080
+134% +$470K ﹤0.01% 3707
2016
Q1 		$272K Buy
9,791
+1,834
+23% +$61.1K ﹤0.01% 5224
2015
Q4 		$428K Sell
7,957
-46,086
-85% -$2.32M ﹤0.01% 4680
2015
Q3 		$2.16M Buy
54,043
+46,710
+637% +$1.52M ﹤0.01% 2843
2015
Q2 		$234K Sell
7,333
-118,390
-94% -$3M ﹤0.01% 6108
2015
Q1 		$3M Buy
+125,723
New +$2.82M ﹤0.01% 2589

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's ITCI Position: Q2 2025 in Review

Citadel Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,237,131 shares — an estimated $295M sold.

Citadel Advisors first reported a position in ITCI in Q1 2015 and held it in 40 quarters. The position peaked at $295M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Citadel Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 2,237,131 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $295M.
  • Citadel Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 40 quarters.
  • Citadel Advisors's Intra-Cellular Therapies Inc. position peaked at $295M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.